- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02070120
저 위험 방광암 수술 대신 방광 화학 요법 조사 (CALIBER)
CALIBER - 저위험 비근육 침습성 방광암의 화학절제술 및 외과적 관리에 대한 2상 무작위 타당성 연구
Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic. This multicentre study aims to establish the short term efficacy of chemoresection using chemotherapy within the bladder for the treatment of NMIBC.
Should the levels of complete response following chemoresection meet predefined criteria, a larger phase III trial would be developed to assess longer term disease related endpoints, with the aim of standardising management of recurrent low risk NMIBC and potentially removing the need for over a thousand patients each year to undergo surgery.
연구 개요
상세 설명
CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study.
Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between chemoresection and surgical management.
Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment should continue, 9 additional participants will be recruited, all of whom will receive chemoresection.
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via catheter under local anaesthetic.
Patients assigned to the surgical management group will receive the standard surgical management in use at their hospital for treatment of recurrence which may include a single post-operative installation of 40mg MMC within 24 hours.
All participants will be followed up at 3 weeks from the start of treatment (ie at time of final MMC instillation for chemoresection group) and each will receive a cystoscopy three months from the end of treatment to assess response, in accordance with European Association of Urology (EAU) guidelines.
Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free at 3 months and then annually.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
London, 영국, NW1 2BU
- University College Hospital
-
Manchester, 영국, M23 9LT
- Wythenshawe Hospital
-
Manchester, 영국, M20 2LR
- Withington Hospital
-
-
Cheshire
-
Macclesfield, Cheshire, 영국, SK10 3BL
- Macclesfield District General Hospital
-
-
Cleveland
-
Middlesbrough, Cleveland, 영국, TS4 3BW
- James Cook University Hospital
-
-
Cumbria
-
Whitehaven, Cumbria, 영국, CA28 8JG
- West Cumberland Hospital
-
-
Devon
-
Exeter, Devon, 영국, EX2 5DW
- Royal Devon and Exeter Hospital
-
Plymouth, Devon, 영국, PL6 8DH
- Derriford Hospital
-
-
Dorset
-
Bournemouth, Dorset, 영국, BH7 7DW
- Royal Bournemouth Hospital
-
Dorchester, Dorset, 영국, DT1 2JY
- Dorset County Hospital
-
-
England
-
Carlisle, England, 영국, CA2 7HY
- Cumberland Infirmary
-
-
Essex
-
Chelmsford, Essex, 영국, CM1 5ET
- Broomfield Hospital
-
Harlow, Essex, 영국, CM20 1QX
- Princess Alexandra Hospital
-
-
Gloucestershire
-
Cheltenham, Gloucestershire, 영국, GL53 7AN
- Cheltenham General Hospital
-
Gloucester, Gloucestershire, 영국, GL1 3NN
- Gloucestershire Royal Hospital
-
-
Greater Manchester
-
Manchester, Greater Manchester, 영국, OL1 2JH
- Royal Oldham Hospital
-
-
Hampshire
-
Basingstoke, Hampshire, 영국, RG24 9NA
- Basingstoke and North Hampshire Hospital
-
Southampton, Hampshire, 영국, SO16 6YD
- Southampton General Hospital
-
-
Herefordshire
-
Hereford, Herefordshire, 영국, HR1 2ER
- Hereford County Hospital
-
-
Kent
-
Dartford, Kent, 영국, DA2 8DA
- Darent Valley Hospital
-
Gillingham, Kent, 영국, ME7 5NY
- Medway Maritime Hospital
-
-
Lancashire
-
Preston, Lancashire, 영국, PR2 9HT
- Royal Preston Hospital
-
-
Leicestershire
-
Leicester, Leicestershire, 영국, LE5 4PW
- Leicester General Hospital
-
-
Middlesex
-
Harrow, Middlesex, 영국, HA1 3UJ
- Northwick Park Hospital
-
-
Oxfordshire
-
Headington, Oxfordshire, 영국, OX3 7LE
- Churchill Hospital
-
-
South Yorkshire
-
Sheffield, South Yorkshire, 영국, S10 2JF
- Royal Hallamshire Hospital
-
-
Suffolk
-
Ipswich, Suffolk, 영국, IP4 5PD
- Ipswich Hospital
-
-
Surrey
-
Croydon, Surrey, 영국, CR7 7YE
- Croydon University Hospital
-
Guildford, Surrey, 영국, GU2 7XX
- Royal Surrey County Hospital
-
-
Tyne and Wear
-
Newcastle upon Tyne, Tyne and Wear, 영국, NE7 7DN
- Freeman Hospital
-
-
West Midlands
-
Wolverhampton, West Midlands, 영국, WV10 0QP
- New Cross Hospital
-
-
West Sussex
-
Chichester, West Sussex, 영국, PO19 6SE
- St Richard's Hospital
-
Worthing, West Sussex, 영국, BN11 2DH
- Worthing Hospital
-
-
West Yorkshire
-
Wakefield, West Yorkshire, 영국, WF1 4DG
- Pinderfields General Hospital
-
-
Worcestershire
-
Kidderminster, Worcestershire, 영국, DY11 6RJ
- Kidderminster Hospital
-
Redditch, Worcestershire, 영국, B98 7UB
- Alexandra Hospital
-
Worcester, Worcestershire, 영국, WR5 1DD
- Worcester Royal Hospital
-
-
Yorkshire
-
Leeds, Yorkshire, 영국, LS9 7TF
- St James's University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Written informed consent
- NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables
- Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis
- Aged 16 or over
- Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit of Normal (ULN)
- Negative pregnancy test for women of child-bearing potential
Exclusion Criteria:
- Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
- Any history of histologically confirmed non-TCC bladder cancer
- Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
- Any prior treatment of the trial entry recurrence (including biopsy)
- Previous MMC chemotherapy other than a single instillation at diagnostic surgery
- Known allergy to MMC
- Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
- Known or suspected reduced bladder capacity (<100ml)
- Significant bleeding disorder
- Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
- Active or intractable urinary tract infection
- Urethral stricture or anything impeding the insertion of a catheter
- Large narrow neck diverticula
- Significant urinary incontinence
- Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
- Unable or unwilling to comply with study procedures or follow up schedule
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Chemoresection
4 once weekly outpatient intravesical instillations 40mg Mitomycin C |
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
다른 이름들:
|
|
다른: Surgical Management
Surgical management according to local practice |
Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Complete response rate with chemoresection
기간: 3 months
|
Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response. |
3 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment compliance in chemoresection group
기간: Duration of treatment (3 weeks)
|
Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant. |
Duration of treatment (3 weeks)
|
|
Salvage surgery rates
기간: 3 years
|
Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups |
3 years
|
|
Progression-free survival
기간: 3 years
|
Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause. |
3 years
|
|
Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))
기간: up to 12 months
|
Measuring side effects of both treatments using clinician reported toxicity scales |
up to 12 months
|
|
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire
기간: up to 12 months
|
Assessing side effects and impact of both treatments on patient reported quality of life. |
up to 12 months
|
|
Health service utilisation
기간: up to 12 months
|
Assessed using prospective data collection of health resource usage. |
up to 12 months
|
|
Recurrence free interval
기간: up to 12 months
|
Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months |
up to 12 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Hugh Mostafid, Royal Surrey County Hospital NHS Foundation Trust
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ICR-CTSU/2013/10041
- 2013-005095-18 (EudraCT 번호)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .